Case Report of Fatal Immune-Mediated Myocarditis Following Treatment with Davoceticept (ALPN-202), a PD-L1-dependent CD28 Costimulator and Dual PD-L1/CTLA-4 Checkpoint Inhibitor, in Combination with Pembrolizumab
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2024)
关键词
Immune Checkpoint Inhibitor,Immune related adverse event - irAE
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要